EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Financing/Bond
Marinomed Biotech AG: Agreement on the key terms of the issue of a secured
EUR 2.5mn convertible bond
01-Sep-2025 / 11:56 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the
Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS
Group.
The issuer is solely responsible for the content of this announcement.
══════════════════════════════════════════════════════════════════════════
Ad hoc announcement
Marinomed Biotech AG: Agreement on the key terms of the issue of a secured
EUR 2.5mn convertible bond
Korneuburg, September 1, 2025 - Marinomed Biotech AG (the "Company")
announces that it has reached a basic agreement with an investor based in
Germany on the key terms of an intended issue of convertible bonds to be
secured by selected receivables and patents in a nominal value of EUR
2,500,000 and a term of 12 months (extendable to 24 months), which are to
be subscribed exclusively by the investor (subject to the exclusion of
existing shareholders' subscription rights). The convertible bond shall
bear interest at 8.5%, with interest payable at maturity and not being
subject to any conversion rights. The convertible bond shall provide for a
conversion right into shares of the Company at a conversion price of EUR
15 per share (corresponding to a conversion right in up to 166,666 shares
of the Company). The convertible bond is intended to be issued in
September 2025 and is inter alia subject to the suspensive condition of
the required resolutions of an extraordinary shareholders meeting of the
Company to be convoked at short notice. The extraordinary shareholders
meeting shall in particular resolve on the authorization of the management
board to issue the convertible bond subject to the supervisory board's
consent, on the exclusion of shareholders' subscription rights as well as
a new conditional capital for underlying the conversion claims under the
convertible bond. In the event of conversion of the convertible bond, it
is intended to convert the shares from the Company's conditional capital
to be resolved. Marinomed is also evaluating further financing options.
+++ End of ad-hoc announcement +++
About Marinomed Biotech AG
Marinomed Biotech AG is an Austrian, science-based biotech company with a
growing development pipeline. The Company develops innovative
patent-protected products based on the Marinosolv® platform. The
Marinosolv® technology improves the solubility and bioavailability of
hardly soluble compounds and is used to develop new therapeutics for
autoreactive immune disorders. The Company is headquartered in Korneuburg,
Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For
further information, please visit: https://www.marinomed.com.
For further inquiries contact:
Marinomed Biotech AG
PR: Luca Horinek
IR.: Tobias Meister
T: +43 2262 90300 158
E-Mail: (1)pr@marinomed.com
E-Mail: (2)ir@marinomed.com
Disclaimer
This press release contains forward-looking statements, which are based on
current views, expectations and projections of the management of Marinomed
Biotech AG about future events. These forward-looking statements are
subject to risks, uncertainties and assumptions that could cause actual
results, performance or events to differ materially from those described
in, or expressed or implied by, such statements. The current views,
expectations and projections of the management of Marinomed Biotech AG may
be identified by the context of such statements or words such as
“anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project”
and “target”. Forward-looking statements are only valid as of the date
they are made and Marinomed Biotech AG does not assume any obligation to
update, review or revise any forward-looking statements contained in this
press release whether as a result of new information, future developments
or otherwise. Marinomed, Marinosolv® and Carragelose® are registered
trademarks of Marinomed Biotech AG. These trademarks may be owned or
licensed in select locations only.
End of Inside Information
══════════════════════════════════════════════════════════════════════════
01-Sep-2025 CET/CEST News transmitted by EQS Group. www.eqs.com
══════════════════════════════════════════════════════════════════════════
Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
(Official Market)
EQS News ID: 2191342
End of Announcement EQS News Service
2191342 01-Sep-2025 CET/CEST
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2191342&application_name=news&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf
References
Visible links
1. mailto:pr@marinomed.com
2. mailto:ir@marinomed.com
OTS original text press release with the exclusive in terms of content of the sender – www.ots.at |